Cardiac and Liver Crosstalk in Fibrosis: Who Is the "Brains" of the Operation?

Description

Cardiovascular disease is the leading cause of death among patients with MASH. The mechanisms by which liver fibrosis due to MASH promotes cardiovascular disease are not clear. Moreover, emerging data suggest that cardiac disease may promote liver fibrosis progression. In this session, speakers provide a clinical overview of the association between MASH-related fibrosis/cirrhosis and cardiovascular disease, and dissect potential underlying mechanisms.
 

Journey Maps

Presentations

8:00 AM - 8:15 AM
Nov 08 2025
Washington, D.C.

Common Fibrotic Mechanisms Between the Liver and the Heart

Leila Gobejishvili, Presenter
Basic Science
8:15 AM - 8:30 AM
Nov 08 2025
Washington, D.C.

Association of Metabolic Dysfunction-Associated Steatohepatitis Fibrosis With Cardiovascular Outcomes

Kathleen E Corey, MD, MPH, MMSc, Presenter
Basic Science
8:30 AM - 8:45 AM
Nov 08 2025
Washington, D.C.

Cardiovascular Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease: Dissecting Molecular Mechanisms

David A Brenner, MD, Presenter
Basic Science
8:45 AM - 9:00 AM
Nov 08 2025
Washington, D.C.

It Is Not What but How: Differing Mechanisms of Liver Fat Accumulation Are Associated With Different Cardiovascular Risk

Hanieh Hanieh Yaghootkar, Presenter
Basic Science

Objectives

  • Explain how liver fibrosis impacts cardiovascular disease.
  • Review the impact of cardiovascular disease on liver fibrosis.
  • Discuss how genetics inform mechanisms of hepatic steatosis and predict liver and cardiovascular outcomes.
Chair

Meena B Bansal, MD, FAASLD

Icahn School of Medicine at Mount Sinai (ISMMS)